On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) for younger patients.

The approval covers pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS).

FDA Expands Novartis Cosentyx Label To Pediatric HS Patients

HS is a chronic, systemic inflammatory skin disease that causes recurring boil-like lesions, which can rupture into painful wounds and lead to scarring. 

HS affects as many as 1 in 100 people worldwide and often begins around puberty.

"With more than a decade of real-world experience across multiple autoimmune diseases, Cosentyx is a well-established treatment option that many physicians trust," said Victor ...